

Haematologica  
HAEMATOL/2016/146654  
Version 3

Antiplatelet therapy versus observation in low-risk essential  
thrombocythemia with CALR mutation

Alberto Alvarez-Larrán, Arturo Pereira, Paola Guglielmelli, Juan Carlos Hernández-Boluda, Eduardo Arellano-Rodrigo, Francisca Ferrer-Marín, Alimam Samah, Martin Griesshammer, Ana Kerguelen, Bjorn Andreasson, Carmen Burgaleta, Jiri Schwarz, Valentín García-Gutiérrez, Rosa Ayala, Pere Barba, María Teresa Gómez-Casares, Chiara Paoli, Beatrice Drexler, Sonja Zweegman, Mary F. McMullin, Jan Samuelsson, Claire Harrison, Francisco Cervantes, Alessandro M. Vannucchi, and Carlos Besses

Disclosures: The authors have no relevant conflict of interest to declare regarding this article

Contributions: AAL designed the study, collected the data, performed the statistical analysis, analyzed and interpreted the results and wrote the paper. AP designed the study, performed the statistical analysis, analyzed and interpreted the results and wrote the paper. PG, JCHB, EAR, FFM, AS, MG, AK, BA, CB, JS, VGG, RA, PB, MTGCa, CP, BD, SZ, MFM, JS, CH, FC, AV and CB collected the data, revised the manuscript and approved the final version